Home
Clinical Trials
Quality Of Life While Receivi...

Quality Of Life While Receiving Faslodex

Last Updated: 2009-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

NCT00328120

Advanced Breast Cancer

COMPLETED PHASE1

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

NCT00681369

Breast Cancer

COMPLETED

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

NCT00274469

Metastatic Breast Cancer

COMPLETED PHASE2

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

NCT00570323

Breast Cancer

COMPLETED PHASE2

Second Line Breast Cancer Trial

NCT00635713

Advanced Breast Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologic and/or cytological proven breast cancer.
* Patients with metastases of breast cancer ± postmenopausal primary tumor ≥12 months.
* Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor.
* ECOG performance status of ≤ 2
* Patient willingness to take part in the programm
* Life expectancy of more than 6 months.
* Patient ability to complete a questionnaire.

Exclusion Criteria

* Contraindications for Faslodex therapy
* Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers